Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature.

Literature DB >> 9290809

Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature.

R Shapiro¹, V P Scantlebury, M L Jordan, C Vivas, H A Gritsch, J McCauley, J J Fung, T R Hakala, R L Simmons, T E Starzl.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 1997 PMID： 9290809 PMCID： PMC2981101 DOI： 10.1016/s0041-1345(97)00576-9

Source DB: PubMed Journal: Transplant Proc ISSN： 0041-1345 Impact factor: 1.066

× No keyword cloud information.

14 in total

1. New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients.

Authors: V Scantlebury; R Shapiro; J Fung; A Tzakis; J McCauley; M Jordan; C Jensen; T Hakala; R Simmons; T E Starzl
Journal: Transplant Proc Date: 1991-12 Impact factor: 1.066

2. A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients.

Authors: R Shapiro; M L Jordan; V P Scantlebury; C Vivas; J J Fung; J McCauley; P Randhawa; A J Demetris; W Irish; A Jain
Journal: Transplant Proc Date: 1995-02 Impact factor: 1.066

3. Inhibition of insulin production by FK 506 is caused at the transcriptional level in pancreatic beta cell when FK BP-12 content is relatively high.

Authors: K Tamura; T Fujimura; T Tsutsumi; K Nakamura; T Ogawa; C Atumaru; Y Hirano; K Ohara; K Ohtsuka; K Shimomura
Journal: Transplant Proc Date: 1995-02 Impact factor: 1.066

4. Three years of follow-up of bone marrow-augmented organ transplant recipients: the impact on donor-specific immune modulation.

Authors: A Zeevi; M Pavlick; R Banas; C Bentlejewski; K Spichty; A S Rao; P Fontes; A Iyengar; R Shapiro; F Dodson; M Jordan; S Pham; R Keenan; B Griffith; R Corry; F Egidi; J J Fung; T E Starzl
Journal: Transplant Proc Date: 1997 Feb-Mar Impact factor: 1.066

5. FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group.

Authors: J Miller; J D Pirsch; M Deierhoi; F Vincenti; R S Filo
Journal: Transplant Proc Date: 1997 Feb-Mar Impact factor: 1.066

Review 6. Tacrolimus (FK-506) in kidney transplantation.

Authors: R Shapiro
Journal: Transplant Proc Date: 1997 Feb-Mar Impact factor: 1.066

7. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.

Authors: J D Pirsch; J Miller; M H Deierhoi; F Vincenti; R S Filo
Journal: Transplantation Date: 1997-04-15 Impact factor: 4.939

8. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival.

Authors: D W Gjertson; J M Cecka; P I Terasaki
Journal: Transplantation Date: 1995-12-27 Impact factor: 4.939

9. Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?

Authors: R Gunnarsson; G Lundgren; G Magnusson; L Ost; C G Groth
Journal: Scand J Urol Nephrol Suppl Date: 1980

10. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell.

Authors: K Tamura; T Fujimura; T Tsutsumi; K Nakamura; T Ogawa; C Atumaru; Y Hirano; K Ohara; K Ohtsuka; K Shimomura
Journal: Transplantation Date: 1995-06-15 Impact factor: 4.939

7 in total

7. Predictive factors associated with the reversibility of post-transplantation diabetes mellitus following liver transplantation.

Authors: Hwa Young Ahn; Young Min Cho; Nam-Joon Yi; Kyung Suk Suh; Kuhn Uk Lee; Kyong Soo Park; Seong Yeon Kim; Hong Kyu Lee
Journal: J Korean Med Sci Date: 2009-07-29 Impact factor: 2.153

7 in total

Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature.

1. New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients.

2. A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients.

3. Inhibition of insulin production by FK 506 is caused at the transcriptional level in pancreatic beta cell when FK BP-12 content is relatively high.

4. Three years of follow-up of bone marrow-augmented organ transplant recipients: the impact on donor-specific immune modulation.

5. FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group.

Review 6. Tacrolimus (FK-506) in kidney transplantation.

7. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.

8. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival.

9. Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?

10. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell.

1. New-Onset Diabetes Mellitus After Transplantation in a Cynomolgus Macaque (Macaca fasicularis).

2. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.

3. Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression.

Review 4. [Diabetes and heart transplantation].

5. Pediatric renal transplantation under tacrolimus-based immunosuppression.

6. Long-term results of pancreas transplantation under tacrolius immunosuppression.

7. Predictive factors associated with the reversibility of post-transplantation diabetes mellitus following liver transplantation.